Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs

R Roskoski Jr - Pharmacological research, 2016 - Elsevier
Cyclins and cyclin-dependent protein kinases (CDKs) are important regulatory components
that are required for cell cycle progression. The levels of the cell cycle CDKs are generally …

Oncogenic and tumor suppressive components of the cell cycle in breast cancer progression and prognosis

D Kashyap, VK Garg, EN Sandberg, N Goel… - Pharmaceutics, 2021 - mdpi.com
Cancer, a disease of inappropriate cell proliferation, is strongly interconnected with the cell
cycle. All cancers consist of an abnormal accumulation of neoplastic cells, which are …

[HTML][HTML] Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis

S Li, Y Shen, M Wang, J Yang, M Lv, P Li, Z Chen… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Various studies have evaluated the significance of PTEN (phosphatase and tensin homolog
deleted from chromosome 10) expression in breast cancer, but their results remain …

Cell cycle dysregulation in breast cancer

MA Mir, SU Khan, S Aisha - Therapeutic potential of cell cycle kinases in …, 2023 - Springer
Cancer, a condition characterized by abnormal cell growth, is closely linked to the cell cycle.
In reaction to mitogenic cues, all malignancies comprise an aberrant buildup of tumor …

[HTML][HTML] Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27

M Wan, W Huang, TE Kute, LD Miller, Q Zhang… - The American journal of …, 2012 - Elsevier
Yin Yang 1 (YY1) is highly expressed in various types of cancers and regulates
tumorigenesis through multiple pathways. In the present study, we evaluated YY1 …

Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial

M Feldt, O Bjarnadottir, S Kimbung, K Jirström… - Journal of translational …, 2015 - Springer
Purpose Cholesterol lowering statins have been demonstrated to exert anti-tumoral effects
on breast cancer by decreasing proliferation as measured by Ki67. The biological …

[HTML][HTML] An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer

AM Elshazly, DA Gewirtz - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Breast cancer (BC) is the second most common cause of cancer-related deaths and the
most frequently diagnosed cancer in females. Among breast cancer types, HER2-positive …

The PTEN and ATM axis controls the G1/S cell cycle checkpoint and tumorigenesis in HER2-positive breast cancer

C Bassi, J Fortin, BE Snow, A Wakeham, J Ho… - Cell Death & …, 2021 - nature.com
The tumor suppressor PTEN is disrupted in a large proportion of cancers, including in HER2-
positive breast cancer, where its loss is associated with resistance to therapy. Upon …

The proliferative activity of mammary epithelial cells in normal tissue predicts breast cancer risk in premenopausal women

SJ Huh, H Oh, MA Peterson, V Almendro, R Hu… - Cancer research, 2016 - AACR
The frequency and proliferative activity of tissue-specific stem and progenitor cells are
suggested to correlate with cancer risk. In this study, we investigated the association …

miR‑221‑3p promotes the cell growth of non‑small cell lung cancer by targeting p27

G Yin, B Zhang, J Li - Molecular Medicine Reports, 2019 - spandidos-publications.com
Emerging evidence suggests the critical function of microRNAs in regulating the growth of
cancer cells. In the present study, it was demonstrated that miR‑221‑3p was overexpressed …